▼Lansoprazole - another proton pump inhibitor
- 1 May 1995
- journal article
- clinical trial
- Published by BMJ in Drug and Therapeutics Bulletin
- Vol. 33 (5) , 36-37
- https://doi.org/10.1136/dtb.1995.33536
Abstract
Lansoprazole (Zoton - Lederle) is a proton pump inhibitor recently licensed for the treatment of duodenal ulcer, benign gastric ulcer or reflux oesophagitis. It is structurally related to omeprazole, which has now been available in the UK for 6 years. In this article we consider the place of lansoprazole in the treatment of patients with acid-related digestive tract disorders.Keywords
This publication has 8 references indexed in Scilit:
- Comparison of the efficacy and safety of lansoprazole 30 mg and oemprazole 40 mg in patients with acute reflux oesophagitis Grade II, III and IVa: a Dutch multicenter studyThe Netherlands Journal of Medicine, 1995
- Lansoprazole versus ranitidine for the treatment of reflux oesophagitisAlimentary Pharmacology & Therapeutics, 1995
- A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitisAlimentary Pharmacology & Therapeutics, 1995
- Efficacy and safety of lansoprazole in the treatment of gastric ulcerEuropean Journal of Gastroenterology & Hepatology, 1994
- LansoprazoleDrugs, 1994
- Rapid healing of gastric ulcers with lansoprazoleAlimentary Pharmacology & Therapeutics, 1994
- Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine.Gut, 1993
- Lansoprazole versus Omeprazole in Short-Term Treatment of Reflux Oesophagitis Results of a Scandinavian Multicentre TrialScandinavian Journal of Gastroenterology, 1993